RKI-1313

RKI-1313 is a small-molecule inhibitor of Rho-associated coiled-coil–containing protein kinases (ROCK1 and ROCK2), with moderate selectivity for ROCK2 (IC50 values of 34 µM and 8 µM, respectively). Developed by the H. Lee Moffitt Cancer Center & Research Institute, RKI-1313 is a structurally-related analog of the more potent ROCK inhibitor RKI-1447. Due to its relatively weak potency and minimal effect on downstream phenotypes such as substrate phosphorylation, cell migration, invasion, and anchorage-independent growth, RKI-1313 is primarily utilized as a negative control or chemical probe in research settings to delineate ROCK-dependent signaling pathways in cancer models.

Other names

N-[(3-methoxyphenyl)methyl]-N'-[4-(4-pyridinyl)-2-thiazolyl]-urea